Deep Apple Therapeutics is pioneering a novel approach to drug discovery by leveraging advanced technologies that integrate deep learning with structural biology. The company utilizes ensemble cryo-electron microscopy (cryo-EM) to explore the conformations of receptors, enabling a deeper understanding of protein dynamics and interactions. This is complemented by AI-powered pocket extraction and molecular dynamics modeling, which together facilitate the identification of biologically relevant binding sites. Deep Apple’s platform conducts virtual screenings of multi-billion molecule libraries, allowing for rapid identification of potential drug candidates that target well-validated biological pathways across various diseases, particularly focusing on GPCR modulators relevant to metabolic, inflammatory, and endocrine disorders.

Since its inception in 2022, Deep Apple has developed a robust pipeline of therapeutic programs by employing a unique deep learning drug discovery engine. This engine is designed to optimize the drug discovery process, significantly reducing the time from target identification to lead optimization to less than 12 months. The company’s proprietary Orchard.ai™ algorithm generates vast, project-specific virtual libraries, which are screened in silico to discover novel small molecules with desirable properties. The integration of wet-lab validation with computational models ensures continuous improvement in predictive performance, positioning Deep Apple as a leader in the rapid and effective discovery of therapeutics for complex diseases.

United States

Deep Apple Therapeutics is writing a new playbook for drug discovery, leveraging a powerful combination of cryo-EM enabled structural biology, AI-powered pocket extraction, and more. The company is advancing multiple programs focused on GPCR modulators, a proven target class with applications in metabolic disorders.

Deep Apple Therapeutics

Company Details